IONS

Business Context and Reporting Period

Company: Isis Pharmaceuticals, Inc. (now Ionis Pharmaceuticals)

Filing Type: Form 10-K (Annual Report)

Period Ended: December 31, 2007

Isis is a biopharmaceutical company focused on the discovery and development of antisense drugs. The company operates two primary segments: Drug Discovery and Development, which targets cardiovascular, metabolic, and cancer diseases, and Ibis Biosciences, a subsidiary developing biosensor technology for infectious disease identification. The company's strategy relies on discovering drugs and licensing them to pharmaceutical partners to fund operations and share commercial risk.

Key Financial Metrics

Note: The significant increase in Net Loss Applicable to Common Stock in 2007 was driven by a $125.3 million non-cash charge related to the acquisition of Symphony GenIsis, Inc., which did not affect the reported Net Loss.

Material Changes vs. Prior Period

• Revenue Surge: Total revenue increased 184% to $69.6 million, primarily due to a $26.5 million sublicensing fee from Alnylam (related to a Roche transaction) and new collaborations with Bristol-Myers Squibb (BMS) and Ortho-McNeil (OMI).
• Improved Operating Loss: The reported Net Loss decreased significantly from $45.9 million in 2006 to $11.0 million in 2007, reflecting higher revenue and lower interest expense following debt refinancing.
• Debt Refinancing: The company issued $162.5 million in 2 5/8% convertible subordinated notes and used proceeds to repay $125 million in 5 1/2% notes, reducing annual cash interest payments by approximately $2.6 million.
• Strategic Acquisitions: In September 2007, Isis purchased Symphony GenIsis, Inc. for $120 million ($80.4 million cash and stock), regaining full ownership of key drug assets (mipomersen and diabetes drugs) previously licensed to Symphony.

Guidance, Outlook, and Management Commentary

• Partnership Strategy: Management highlighted a successful year of partnerships, securing nearly $450 million in upfront cash payments and potential milestones exceeding $1.9 billion. Key deals included licensing mipomersen to Genzyme (announced Jan 2008) and diabetes drugs to OMI.
• Liquidity Outlook: Based on existing cash and committed payments (including the Genzyme deal), management expects a year-end 2008 cash balance greater than $450 million, sufficient to fund operations for at least five years.
• Drug Pipeline Progress:
  • Mipomersen: Advanced to pivotal studies for familial hypercholesterolemia; licensed to Genzyme with profit-sharing rights.
  • Metabolic Franchise: Expanded with Phase 1 studies for ISIS 325568 (GCGR) and ISIS 377131 (GCCR) partnered with OMI.
  • Ibis Biosciences: Entered a strategic alliance with Abbott Molecular, which invested $20 million and received an option to acquire the remaining equity for up to $230 million.
• Risks: The company faces risks related to the failure of clinical trials, the ability to secure future funding, and the performance of partners (e.g., a dispute with Bruker Daltonics regarding Ibis manufacturing).

Important Facts for Investor Verification

• Non-Cash Charges: Verify the impact of the $125.3 million "Excess Purchase Price" charge on Net Loss Applicable to Common Stock, which distorted the per-share loss metric despite a strong operating cash position.
• Deferred Revenue: Confirm the amortization schedules for large upfront payments from Genzyme, OMI, and BMS, which will drive future revenue recognition.
• Debt Covenants: Review the liquidity requirements of the Silicon Valley Bank term loan and the terms of the new convertible notes.
• Partner Performance: Monitor the status of the dispute with Bruker Daltonics regarding the Ibis T5000 Biosensor System and the progress of the Genzyme and OMI collaborations.
• Regulatory Milestones: Track the timeline for the NDA filing for mipomersen (anticipated 2009) and Phase 2 results for diabetes candidates.